Olympiad Research LP Makes New $211,000 Investment in Simulations Plus, Inc. (NASDAQ:SLP)

Olympiad Research LP bought a new position in shares of Simulations Plus, Inc. (NASDAQ:SLP) during the fourth quarter, Holdings Channel reports. The fund bought 7,560 shares of the technology company’s stock, valued at approximately $211,000.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Barclays PLC increased its position in shares of Simulations Plus by 390.6% during the third quarter. Barclays PLC now owns 28,473 shares of the technology company’s stock worth $911,000 after buying an additional 22,669 shares during the period. Geode Capital Management LLC increased its position in shares of Simulations Plus by 4.4% during the third quarter. Geode Capital Management LLC now owns 448,618 shares of the technology company’s stock worth $14,367,000 after buying an additional 18,924 shares during the period. State Street Corp increased its position in shares of Simulations Plus by 4.7% during the third quarter. State Street Corp now owns 640,303 shares of the technology company’s stock worth $20,503,000 after buying an additional 28,953 shares during the period. JPMorgan Chase & Co. increased its position in shares of Simulations Plus by 106.0% during the third quarter. JPMorgan Chase & Co. now owns 47,365 shares of the technology company’s stock worth $1,517,000 after buying an additional 24,371 shares during the period. Finally, BNP Paribas Financial Markets increased its position in shares of Simulations Plus by 402.9% during the third quarter. BNP Paribas Financial Markets now owns 39,944 shares of the technology company’s stock worth $1,279,000 after buying an additional 32,002 shares during the period. 78.08% of the stock is owned by institutional investors.

Insider Buying and Selling at Simulations Plus

In other Simulations Plus news, Director Walter S. Woltosz sold 20,000 shares of the firm’s stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $33.91, for a total value of $678,200.00. Following the transaction, the director now directly owns 3,402,584 shares of the company’s stock, valued at approximately $115,381,623.44. This trade represents a 0.58 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 19.40% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on SLP shares. StockNews.com cut shares of Simulations Plus from a “hold” rating to a “sell” rating in a research report on Monday, November 4th. KeyCorp raised their price target on shares of Simulations Plus from $35.00 to $37.00 and gave the stock an “overweight” rating in a report on Friday, January 24th. Stephens initiated coverage on shares of Simulations Plus in a report on Friday, November 15th. They issued an “overweight” rating and a $39.00 price target for the company. Finally, William Blair restated an “outperform” rating on shares of Simulations Plus in a report on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Simulations Plus currently has an average rating of “Moderate Buy” and an average target price of $49.40.

Simulations Plus Trading Down 0.2 %

Simulations Plus stock opened at $31.77 on Monday. Simulations Plus, Inc. has a 1-year low of $24.00 and a 1-year high of $51.22. The firm has a market capitalization of $638.32 million, a price-to-earnings ratio of 79.43 and a beta of 0.83. The firm’s fifty day moving average price is $31.71 and its two-hundred day moving average price is $32.09.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.